1465-3249
Bimonthly
No
1477-2566
CYTOTHERAPY
1999
126
NORWAY
http://informahealthcare.com/loi/cyt
偏慢,4-8周审稿时间
2区中科院分区
较易平均录用比例
3.2影响因子
生物工程与应用微生物小学科
29/98JIF RANK
6691总被引频次
由泰勒和弗朗西斯集团出版。ISSN: 1465-3249。细胞疗法旨在为读者带来细胞疗法这一快速发展领域的最新发展,并在其医学应用方面教育读者。研究范围包括细胞治疗、移植生物学、干细胞研究、免疫治疗、基因治疗和临床移植,以及实验室的科学、管理和运作。该杂志反映了该领域内的各种科学,并配有全彩插图、数字、流程图和照片,是传播该地区最新发展的一个极好的工具。
http://authorservices.taylorandfrancis.com/category/making-your-submission/
Published by Taylor and Francis Group. ISSN: 1465-3249.Cytotherapy aims to bring readers the very latest developments in the fast-moving field of cellular therapies, and to educate readers in their medical application. Areas covered include cytotherapy, biology of transplantation, stem cell studies, immunotherapy, gene therapy and clinical transplantation, as well as the science, management and operation of the laboratory. The journal reflects the diverse sciences within the field, and with full-colour illustrations, figures, flow charts and photographs, it is an excellent tool for the dissemination of the most recent developments across the area.
大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
医学 | 3区 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 CELL & TISSUE ENGINEERING 细胞与组织工程 HEMATOLOGY 血液学 MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验 CELL BIOLOGY 细胞生物学 | 3区 3区 3区 3区 4区 | 否 | 否 |
JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
Q1 | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | Q1 | 6.196 |
HEMATOLOGY | Q2 | ||
CELL BIOLOGY | Q2 | ||
CELL & TISSUE ENGINEERING | Q2 | ||
MEDICINE, RESEARCH & EXPERIMENTAL | Q2 |
CiteScore | SJR | SNIP | 学科类别 | 分区 | 排名 | 百分位 |
8.00 | 1.004 | 1.014 | 大类:Medicine 小类:Transplantation | Q1 | 5 / 47 |
90% |
大类:Medicine 小类:Oncology | Q1 | 62 / 360 |
82% |
|||
大类:Medicine 小类:Genetics (clinical) | Q1 | 16 / 86 |
81% |
|||
大类:Medicine 小类:Immunology and Allergy | Q2 | 52 / 200 |
74% |
|||
大类:Medicine 小类:Immunology | Q2 | 60 / 213 |
72% |
|||
大类:Medicine 小类:Cell Biology | Q2 | 84 / 274 |
69% |
|||
大类:Medicine 小类:Cancer Research | Q2 | 65 / 210 |
69% |
影响因子 | h-index | Gold OA文章占比 | 研究类文章占比 | OA开放访问 | 平均审稿速度 |
6.196 | 76 | 18.69% | 84.92% | 未开放 | 偏慢,4-8周 |